Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.


PINL:HLOSF - Post by User

Healios KK Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Post by Camaronion Nov 16, 2011 3:15pm
231 Views
Post# 19242665

TD CanadaTrust Calculates Bk/Val @ $0.93

TD CanadaTrust Calculates Bk/Val @ $0.93 Hey The 300, Against this Bk/Val seems unusually low shr price and once that is intentially being held back in the way I described. Can't be just due to lack of interst when it can be baought for this far below book is my thought. Makes me curiouser and curiouser. Thanks for your comments though.Per Share Data Industry Range HLO IndustryEarnings (TTM) -4.5 74.0 -- $2.32Book Value -7.3 75.4
.93 $13.31Cash Flow (TTM) -- -- -- -
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities